Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could arthritis drug humira ease rare skin disease?

NCT ID NCT02113904

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested whether Humira (adalimumab), a drug used for arthritis, can help people with Netherton syndrome, a rare genetic skin condition that causes severe inflammation, itching, and pain. Eleven patients received six injections over three months, followed by three months of monitoring. The goal was to see if the drug could reduce skin symptoms by at least 20% and improve quality of life, while watching for risks like infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Humira (adalimumab)
What this could lead to
If it works, this could point toward a treatment that reduces skin inflammation and improves quality of life for people with Netherton syndrome.
What could go wrong
This is a small, early-phase trial with only 11 people, so results may not apply to everyone. Humira also carries risks like serious infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

11 people

The number who actually took part.

Started

Jan 2014

Finished

Sep 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 4 years of age at the time of enrolment * Patient with a clinical, immuno-histochemical and/or molecular diagnosis confirmed * Vaccinations to date * Informed consent form signed by the patient and/or his parents (or the legal authority) if the patient is a child * Patient with social security coverage Exclusion Criteria: * Ongoing severe infections * Well known allergy to one of Adalimumab ingredients * Allergy to xylocaine * Ongoing treatment to immunosuppressive drugs and biotherapies * History of malignancy * Heart, renal, haematological and/or confirmed hepatic involvement * Pregnant, or breastfeeding, patients * Anomalies of the standard balance sheet: neutropenia \< 1000/mm3, polynucleose \> 12 000 / mm3 - lymphopenia \< 1000 / mm3 - anemia \< 9g / 100ml - thrombocytopenia \< 150 000 /mm3, thrombocytosis \> 500 000/mm3 - transaminase \> 3N

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Netherton syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Netherton syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Netherton syndrome

Contacts and locations

Locations

  • Necker Enfants Malades hospital

    Paris, Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.